Benefits
Body fat and visceral fat 8-week dose-finding RCT
A dose-finding RCT in overweight adults BMI 24-30 at 300/600/900 mg/day showed dose-dependent body fat reductions, a 9.35 cm³ visceral fat area reduction at 900 mg/day, 0.25 kg/m² BMI decrease, and 11 mg/dL LDL-cholesterol reduction. Pivotal foundational dose-finding trial defining the clinical dose range.
12-week body weight loss
300 mg/day produced body weight loss in overweight participants over 12 weeks. Earlier proof-of-concept evidence for sustained weight management at the lower dose.
US visceral fat trial (Nutrafoods)
A manufacturer report (Tominaga 2014) appeared in Nutrafoods, a non-PubMed-indexed industry journal, and is not in this record's references; it is not independent confirmation and should not be presented as replication.
Elderly muscle mass increase
300 mg/day for 8 weeks increased muscle mass in the elderly. Distinguishing finding: muscle mass increase combined with visceral fat reduction — unusual dual benefit among weight-management supplements that typically show only fat reduction. This rests on a single manufacturer-reported study (Kinoshita 2017) that is not indexed in PubMed and is not in this record's references; treat as preliminary, not established, and note it makes no disease-prevention claim.
LDL-cholesterol reduction 11 mg/dL
An 11 mg/dL LDL-cholesterol reduction was documented at 900 mg/day. Lipid profile improvement complement to the body composition effects.
Beta-oxidation enhancement and lipogenesis inhibition
Mechanistic evidence: Glavonoid enhances beta-oxidation (fatty acid metabolism, energy expenditure increase) and inhibits lipogenesis (SCD1 stearoyl-CoA desaturase 1 expression reduction at the adipocyte level). Multi-target metabolic mechanism underlying the body composition improvements.
Mechanism of action
Beta-oxidation enhancement (energy expenditure increase)
Glavonoid enhances mitochondrial fatty acid β-oxidation, increasing energy expenditure via enhanced fatty acid metabolism. This is the mechanistic basis for the observed body fat reduction.
Lipogenesis inhibition
SCD1 (stearoyl-CoA desaturase 1) expression reduction at the adipocyte level inhibits new fat synthesis. Mechanism complement to beta-oxidation: reduces input while increasing output of the adipose energy balance.
Glabridin (3% standardized) bioactive
Standardization to 3% glabridin defines the major flavonoid bioactive — a multi-target compound with anti-obesity, anti-inflammatory, antioxidant, neuroprotective, and anti-melanogenesis activities. The MCT-oil delivery enhances glabridin bioavailability, addressing the ~7.5% oral bioavailability limitation of purified glabridin.
MCT oil delivery (bioavailability)
Medium-chain triglyceride oil (C8:C10 = 99:1) provides lipid-based delivery enhancement. Lipophilic flavonoids absorb better when delivered with fat — and MCTs particularly so given their direct portal vein absorption pathway.
Glycyrrhizin-free composition (safety mechanism)
Critical safety feature: Glavonoid is the flavonoid fraction of licorice, not the glycyrrhizin fraction. Crude licorice contains glycyrrhizin which causes pseudoaldosteronism (hypokalemia, hypertension, edema, heart problems with chronic use) — FDA warns against chronic crude licorice use. Glavonoid excludes glycyrrhizin, allowing chronic use.
Anti-inflammatory effects
NF-κB anti-inflammatory pathway suppression contributes to the broader metabolic and cardiovascular benefits.
Clinical trials
8-week randomized, double-blind, placebo-controlled dose-finding trial (300/600/900 mg/day) in 84 overweight adults (BMI 24-30). Single-manufacturer (Kaneka) industry RCT. (Tominaga Y et al. 2009, Obes Res Clin Pract; PMID 24345587)
84 overweight adults
Tominaga Y et al. 2009 — 8-week dose-finding clinical trial in 84 overweight adults BMI 24-30 at 300/600/900 mg/day Glavonoid. Dose-dependent body fat reductions, 9.35 cm³ visceral fat area reduction at 900 mg/day, 0.25 kg/m² BMI decrease, and 11 mg/dL LDL-cholesterol reduction. Pivotal foundational dose-finding trial (Tominaga Y et al. 2009, Obes Res Clin Pract 3(3):I-IV, PMID 24345587, https://pubmed.ncbi.nlm.nih.gov/24345587/). Single-manufacturer (Kaneka) industry RCT; the only PubMed-indexed trial for this ingredient.